Bladder Cancer

News alerts, weekly reports and conference planners

Related cancers:

‹

Urothelial Cancer (453)

›

No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	cisplatin Sensitive: A1 - Approval cisplatin Sensitive : A1	cisplatin Sensitive: A1 - Approval cisplatin Sensitive : A1
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	nadofaragene firadenovec-vncg Sensitive: A1 - Approval nadofaragene firadenovec-vncg Sensitive : A1	nadofaragene firadenovec-vncg Sensitive: A1 - Approval nadofaragene firadenovec-vncg Sensitive : A1
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
PD-L1 expression	Bladder Cancer	PD-L1 expression	Bladder Cancer	atezolizumab Sensitive: A2 - Guideline atezolizumab Sensitive : A2	atezolizumab Sensitive: A2 - Guideline atezolizumab Sensitive : A2
PD-L1 expression	Bladder Cancer	PD-L1 expression	Bladder Cancer	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	carboplatin + etoposide IV Sensitive: A2 - Guideline carboplatin + etoposide IV Sensitive : A2	carboplatin + etoposide IV Sensitive: A2 - Guideline carboplatin + etoposide IV Sensitive : A2
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	cisplatin + doxorubicin hydrochloride + ifosfamide + etoposide IV Sensitive: A2 - Guideline cisplatin + doxorubicin hydrochloride + ifosfamide + etoposide IV Sensitive : A2	cisplatin + doxorubicin hydrochloride + ifosfamide + etoposide IV Sensitive: A2 - Guideline cisplatin + doxorubicin hydrochloride + ifosfamide + etoposide IV Sensitive : A2
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	5-fluorouracil Sensitive: A2 - Guideline 5-fluorouracil Sensitive : A2	5-fluorouracil Sensitive: A2 - Guideline 5-fluorouracil Sensitive : A2
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	5-fluorouracil + mitomycin Sensitive: A2 - Guideline 5-fluorouracil + mitomycin Sensitive : A2	5-fluorouracil + mitomycin Sensitive: A2 - Guideline 5-fluorouracil + mitomycin Sensitive : A2
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	cisplatin + paclitaxel Sensitive: A2 - Guideline cisplatin + paclitaxel Sensitive : A2	cisplatin + paclitaxel Sensitive: A2 - Guideline cisplatin + paclitaxel Sensitive : A2
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	cisplatin + 5-fluorouracil Sensitive: A2 - Guideline cisplatin + 5-fluorouracil Sensitive : A2	cisplatin + 5-fluorouracil Sensitive: A2 - Guideline cisplatin + 5-fluorouracil Sensitive : A2
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	enfortumab vedotin-ejfv Sensitive: A2 - Guideline enfortumab vedotin-ejfv Sensitive : A2	enfortumab vedotin-ejfv Sensitive: A2 - Guideline enfortumab vedotin-ejfv Sensitive : A2
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	docetaxel Sensitive: A2 - Guideline docetaxel Sensitive : A2	docetaxel Sensitive: A2 - Guideline docetaxel Sensitive : A2
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	paclitaxel Sensitive: A2 - Guideline paclitaxel Sensitive : A2	paclitaxel Sensitive: A2 - Guideline paclitaxel Sensitive : A2
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	gemcitabine + ifosfamide + pegylated liposomal doxorubicin Sensitive: A2 - Guideline gemcitabine + ifosfamide + pegylated liposomal doxorubicin Sensitive : A2	gemcitabine + ifosfamide + pegylated liposomal doxorubicin Sensitive: A2 - Guideline gemcitabine + ifosfamide + pegylated liposomal doxorubicin Sensitive : A2
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	gemcitabine + paclitaxel Sensitive: A2 - Guideline gemcitabine + paclitaxel Sensitive : A2	gemcitabine + paclitaxel Sensitive: A2 - Guideline gemcitabine + paclitaxel Sensitive : A2
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	carboplatin + gemcitabine Sensitive: A2 - Guideline carboplatin + gemcitabine Sensitive : A2	carboplatin + gemcitabine Sensitive: A2 - Guideline carboplatin + gemcitabine Sensitive : A2
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	cisplatin + gemcitabine Sensitive: A2 - Guideline cisplatin + gemcitabine Sensitive : A2	cisplatin + gemcitabine Sensitive: A2 - Guideline cisplatin + gemcitabine Sensitive : A2
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	avelumab Sensitive: A2 - Guideline avelumab Sensitive : A2	avelumab Sensitive: A2 - Guideline avelumab Sensitive : A2
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	sacituzumab govitecan-hziy Sensitive: A2 - Guideline sacituzumab govitecan-hziy Sensitive : A2	sacituzumab govitecan-hziy Sensitive: A2 - Guideline sacituzumab govitecan-hziy Sensitive : A2
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	erdafitinib Sensitive: A2 - Guideline erdafitinib Sensitive : A2	erdafitinib Sensitive: A2 - Guideline erdafitinib Sensitive : A2
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	pembrolizumab + enfortumab vedotin-ejfv Sensitive: A2 - Guideline pembrolizumab + enfortumab vedotin-ejfv Sensitive : A2	pembrolizumab + enfortumab vedotin-ejfv Sensitive: A2 - Guideline pembrolizumab + enfortumab vedotin-ejfv Sensitive : A2
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	nogapendekin alfa inbakicept-pmln Sensitive: B - Late Trials nogapendekin alfa inbakicept-pmln Sensitive : B	nogapendekin alfa inbakicept-pmln Sensitive: B - Late Trials nogapendekin alfa inbakicept-pmln Sensitive : B
PD-L1 expression	Bladder Cancer	PD-L1 expression	Bladder Cancer	nivolumab Sensitive: B - Late Trials nivolumab Sensitive : B	nivolumab Sensitive: B - Late Trials nivolumab Sensitive : B
HLA-A*03	Bladder Cancer	HLA-A*03	Bladder Cancer	CTLA4 inhibitor Resistant: B - Late Trials CTLA4 inhibitor Resistant : B	CTLA4 inhibitor Resistant: B - Late Trials CTLA4 inhibitor Resistant : B
HLA-A*03	Bladder Cancer	HLA-A*03	Bladder Cancer	PD-L1 inhibitor Resistant: B - Late Trials PD-L1 inhibitor Resistant : B	PD-L1 inhibitor Resistant: B - Late Trials PD-L1 inhibitor Resistant : B
HLA-A*03	Bladder Cancer	HLA-A*03	Bladder Cancer	PD1 inhibitor Resistant: B - Late Trials PD1 inhibitor Resistant : B	PD1 inhibitor Resistant: B - Late Trials PD1 inhibitor Resistant : B

Bladder Cancer

Associations(180)

Associations
(180)